Targeting the latent human cytomegalovirus reservoir for T-cell-mediated killing with virus-specific nanobodies
Timo W.M. De Groof, Elizabeth Elder, Eleanor Y. Lim, Raimond Heukers, Nick D. Bergkamp, Ian J. Groves, Mark R. Wills, John Sinclair, Martine J. Smit
Abstract
Latent human cytomegalovirus (HCMV) infection is characterized by limited gene expression, making latent HCMV infections refractory to current treatments targeting viral replication. However, reactivation of latent HCMV in immunosuppressed solid organ and stem cell transplant patients often results in morbidity. Here, we report the killing of latently infected cells via a virus-specific nanobody (VUN100bv) that partially inhibits signaling of the viral receptor US28. VUN100bv reactivates immediate early gene expression in latently infected cells without inducing virus production. This allows recognition and killing of latently infected monocytes by autologous cytotoxic T lymphocytes from HCMV-seropositive individuals, which could serve as a therapy to reduce the HCMV latent reservoir of transplant patients.